<MedlineCitation Status="Completed">
<MedlineID>10011961</MedlineID>
<PMID>217525</PMID>
<DateCreated>
<Year>1979</Year>
<Month>05</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>1979</Year>
<Month>05</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised>
<Year>2000</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0008-543X</ISSN>
<JournalIssue>
<Volume>43</Volume>
<Issue>2</Issue>
<PubDate>
<Year>1979</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>Endometrial findings in postmenopausal women receiving long-term estrogen therapy.</ArticleTitle>
<Pagination>
<MedlinePgn>658-60</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>An histological study of the endometrium of 43 postmenopausal women under the chronic effect of cyclically administered conjugated estrogens was performed. Four atypical hyperplasias and one adenocarcinoma in situ were found. The frequency of these findings is similar to the one found in a sample of the population consulting the gynecologic clinic of our Hospital that never received estrogen therapy.</AbstractText>
</Abstract>
<AuthorList>
<Author>
<LastName>Dabancens</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author>
<LastName>Fuensalida</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author>
<LastName>Gonzalez</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author>
<LastName>Za√±artu</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>Cancer</MedlineTA>
<NlmUniqueID>0374236</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Estrogens, Conjugated</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName>Adenocarcinoma</DescriptorName>
<QualifierName MajorTopicYN="Y">etiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Carcinoma in Situ</DescriptorName>
<QualifierName MajorTopicYN="Y">etiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Comparative Study</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Endometrium</DescriptorName>
<QualifierName MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName>pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Estrogens, Conjugated</DescriptorName>
<QualifierName>administration &#38; dosage</QualifierName>
<QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Human</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Hyperplasia</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Menopause</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Middle Age</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Prospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Uterine Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="Y">etiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
